NASDAQ:KPTI
Karyopharm Therapeutics Inc. Stock News
$0.98
+0.0273 (+2.88%)
At Close: Jun 21, 2024
Karyopharm Therapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
04:05pm, Monday, 03'rd Jun 2024
NEWTON, Mass. , June 3, 2024 /PRNewswire/ -- Karyopharm Therapeutics Inc. (Nasdaq: KPTI), a commercial-stage pharmaceutical company pioneering novel cancer therapies, today announced that the Company
Long-Term Follow-Up Data Signal Promising Progression-Free Survival (PFS) for Selinexor in the Maintenance Setting with Median PFS of 28.4 Months in the TP53 Wild-Type and 39.5 Months in the Proficien
Karyopharm to Participate at the Jefferies Global Healthcare Conference
04:05pm, Wednesday, 29'th May 2024
NEWTON, Mass. , May 29, 2024 /PRNewswire/ -- Karyopharm Therapeutics Inc. (Nasdaq: KPTI), a commercial-stage pharmaceutical company pioneering novel cancer therapies, today announced that the Company'
The Next Novavax? 3 Biopharma Stocks to Buy Before They Boom
06:45am, Thursday, 23'rd May 2024
Novavax (NASDAQ: NVAX ) stock was among the laggards in the race for the vaccine against COVID-19. Unsurprisingly, NVAX stock plunged from highs of $320 in 2021 to recent lows of $3.5.
Karyopharm to Participate at the 2024 RBC Capital Markets Global Healthcare Conference
04:05pm, Wednesday, 08'th May 2024
NEWTON, Mass. , May 8, 2024 /PRNewswire/ -- Karyopharm Therapeutics Inc. (Nasdaq: KPTI), a commercial-stage pharmaceutical company pioneering novel cancer therapies, today announced that the Company's
Karyopharm Therapeutics Inc. (KPTI) Q1 2024 Earnings Call Transcript
03:38pm, Wednesday, 08'th May 2024
Karyopharm Therapeutics Inc. (NASDAQ:KPTI ) Q1 2024 Earnings Conference Call May 8, 2024 8:00 AM ET Company Participants Elhan Webb - Senior Vice President of Investor Relations Richard Paulson - Pres
Karyopharm Reports First Quarter 2024 Financial Results and Highlights Recent Company Progress
07:30am, Wednesday, 08'th May 2024
– Announces Significant Refinancing Transactions and Amends Royalty Agreement with HealthCare Royalty Extending Vast Majority of Its Debt Maturities into 2028 and 2029, Well Beyond Expected Data Rea
– $148.0 Million (86%) of Existing Convertible Notes due in 2025 to be Exchanged for $111.0 Million of New Convertible Notes due in 2029 and Warrants – – Issues New $100.0 Million Senior Secured
Karyopharm to Report First Quarter 2024 Financial Results on May 8, 2024
04:30pm, Thursday, 02'nd May 2024
-- Conference Call Scheduled for Wednesday, May 8, 2024, at 8:00 a.m. ET -- NEWTON, Mass.
Karyopharm Therapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
04:05pm, Wednesday, 01'st May 2024
NEWTON, Mass. , May 1, 2024 /PRNewswire/ -- Karyopharm Therapeutics Inc. (Nasdaq: KPTI), a commercial-stage pharmaceutical company pioneering novel cancer therapies, today announced that the Company g
Karyopharm Therapeutics: Spiraling Despite Upcoming Catalysts
02:28pm, Tuesday, 30'th Apr 2024
Karyopharm Therapeutics Inc.'s selinexor is being featured in 7 presentations at ASCO. The company is also exploring selinexor's potential role in myelofibrosis, with two key trials planned. Karyophar
Karyopharm Announces Presentations in Endometrial Cancer and Myelofibrosis at the 2024 American Society of Clinical Oncology Annual Meeting
04:01pm, Wednesday, 24'th Apr 2024
Invited to Present Updated Endometrial Cancer Data During Special Session "ASCO Plenary Series: Rapid Abstract Updates" NEWTON, Mass. , April 24, 2024 /PRNewswire/ -- Karyopharm Therapeutics Inc. (Nas
Karyopharm Therapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
04:05pm, Monday, 01'st Apr 2024
NEWTON, Mass. , April 1, 2024 /PRNewswire/ -- Karyopharm Therapeutics Inc. (Nasdaq: KPTI), a commercial-stage pharmaceutical company pioneering novel cancer therapies, today announced that the Company
Karyopharm to Participate at Barclays 26th Annual Global Healthcare and Leerink Partners Global Biopharma Conferences
04:05pm, Wednesday, 06'th Mar 2024
NEWTON, Mass. , March 6, 2024 /PRNewswire/ -- Karyopharm Therapeutics Inc. (Nasdaq: KPTI), a commercial-stage pharmaceutical company pioneering novel cancer therapies, today announced that the Company
Karyopharm Therapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
04:05pm, Friday, 01'st Mar 2024
NEWTON, Mass. , March 1, 2024 /PRNewswire/ -- Karyopharm Therapeutics Inc. (Nasdaq: KPTI), a commercial-stage pharmaceutical company pioneering novel cancer therapies, today announced that the Company